Your browser is no longer supported. Please, upgrade your browser.
ERYP ERYTECH Pharma S.A. monthly Stock Chart
Index- P/E- EPS (ttm)-2.79 Insider Own- Shs Outstand19.08M Perf Week-5.67%
Market Cap152.25M Forward P/E- EPS next Y-2.80 Insider Trans- Shs Float10.78M Perf Month30.29%
Income- PEG- EPS next Q- Inst Own7.05% Short Float0.04% Perf Quarter4.65%
Sales- P/S- EPS this Y-12.10% Inst Trans- Short Ratio1.14 Perf Half Y-27.26%
Book/sh10.64 P/B0.75 EPS next Y35.50% ROA- Target Price- Perf Year8.13%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.50 - 13.95 Perf YTD8.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.80% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low128.00% ATR0.62
Employees217 Current Ratio- Sales Q/Q13.60% Oper. Margin- RSI (14)57.98 Volatility9.97% 8.64%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume4.18 Prev Close8.31
ShortableNo LT Debt/Eq- EarningsNov 06 BMO Payout- Avg Volume3.41K Price7.98
Recom1.70 SMA2012.11% SMA5020.00% SMA20014.59% Volume14,249 Change-3.97%
Nov-12-20 04:30PM  
Nov-05-20 04:30PM  
Nov-04-20 12:00PM  
Nov-02-20 03:19AM  
Oct-29-20 05:30PM  
Oct-26-20 05:30PM  
Oct-12-20 05:51AM  
Sep-21-20 04:45PM  
Sep-16-20 04:30PM  
Sep-14-20 04:30PM  
Aug-06-20 12:00PM  
Jul-10-20 12:00PM  
Jun-26-20 04:30PM  
Jun-25-20 08:26AM  
Jun-09-20 12:00PM  
Jun-02-20 04:30PM  
Jun-01-20 01:30AM  
May-26-20 04:00PM  
May-07-20 12:00PM  
May-06-20 04:30PM  
May-05-20 04:30PM  
Apr-30-20 04:30PM  
Apr-28-20 06:13PM  
Apr-20-20 04:30PM  
Apr-06-20 12:00PM  
Mar-19-20 06:00PM  
Mar-16-20 06:05PM  
Mar-12-20 05:30PM  
Mar-06-20 12:00PM  
Feb-26-20 05:00PM  
Feb-20-20 04:30PM  
Feb-04-20 12:00PM  
Feb-03-20 06:43AM  
Jan-24-20 01:30AM  
Jan-14-20 08:29AM  
Jan-10-20 11:45AM  
Dec-02-19 12:00PM  
Nov-25-19 01:30AM  
Nov-14-19 05:00PM  
Nov-07-19 05:00PM  
Nov-05-19 05:00PM  
Nov-04-19 01:30AM  
Oct-04-19 12:00PM  
Sep-18-19 03:54AM  
Sep-17-19 05:00PM  
Sep-11-19 05:00PM  
Sep-03-19 11:51AM  
Aug-02-19 11:45AM  
Jul-23-19 05:07PM  
Jul-16-19 05:02PM  
Jul-02-19 12:01PM  
Jun-26-19 05:01PM  
Jun-24-19 05:32PM  
May-31-19 12:05PM  
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.